Lobe Sciences Ltd.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

• Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience

• Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations

• Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

• The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15^th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with virtual attendance available via Microsoft Teams

• Dr. Frederick D. Sancilio, Executive Chairman and Chief Executive Officer, provided a letter to shareholders including an update on corporate strategy with a focus on uplisting to a senior exchange and an overview of progress across the Company's three subsidiary programs

• Shareholders will be asked to vote on the election of directors, appointment of auditors, approval of a new Long-Term Incentive Plan, ratification of prior restricted share unit grants, and an amendment to the Company's constating documents

• The record date for voting is June 15, 2026, with a proxy/voting instruction deadline of July 28, 2026

• Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders

• The Canadian Securities Exchange has accepted the share issuance, allowing the Company to complete the settlement

• Company remains well-positioned with C$4.96 million in cash and short-term investments as of its most recent quarter ended February 28, 2026

• Subsidiary R&D programs remain on track and on budget, with continued de-risking through Lobe's disciplined development model

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

• Liabilities reduced 81%, from $2.35M to $0.44M

• Cash increased more than 24x, from $0.24M to $5.99M

• Net working capital improved by $6.1M, from ($2.01M) to $4.05M

• Outstanding warrants reduced by ~70%, from 43M to 13M

Balance Sheet and Sharpened Strategy

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

• European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.

• Covers Altemia(R) Medical Food Formula - The patented composition underpins Altemia(R), a physician-supervised medical food formulated to address long-chain fatty acid deficiencies common in SCD patients.

• Supports Global Expansion Strategy - Validation strengthens Lobe's IP portfolio and enables broader commercialization of Altemia(R) across key European markets.

• New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™

• $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addiction

• Option for an additional $20 million investment in Cynaptec Pharmaceuticals to support Phase 3 clinical development

• Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.

• Mr. Yao brings over 25 years of experience across finance and biotech, with executive roles at companies such as Mountain Valley MD and global firms like Scotiabank and Morgan Stanley.

• His appointment marks a strategic shift to full-time financial leadership, aligning with Lobe's commitment to regulatory compliance, capital markets readiness, and operational expansion.

• Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies

• US$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headache

• Lobe creates Cynaptec Pharmaceuticals, Inc. which will own and develop Conjugated Psilocin ^TM